Loading…
60 Degrees Pharmaceuticals, Inc. is projected to decline to $1.53 by 2027, a -2% move from its current price of $1.56. SXTP is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $1.51 | $1.56 | $1.62 | -0.01% |
| Jul 13 | $1.48 | $1.56 | $1.64 | -0.02% |
| Jul 14 | $1.47 | $1.56 | $1.66 | -0.03% |
| Jul 15 | $1.45 | $1.56 | $1.67 | -0.03% |
| Jul 16 | $1.44 | $1.56 | $1.69 | -0.04% |
| Jul 17 | $1.43 | $1.56 | $1.70 | -0.05% |
| Jul 18 | $1.42 | $1.56 | $1.71 | -0.06% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.42 | $1.56 | $1.71 | -0.06% |
| Week 2 | $1.37 | $1.56 | $1.78 | -0.12% |
| Week 3 | $1.33 | $1.56 | $1.83 | -0.18% |
| Week 4 | $1.29 | $1.56 | $1.87 | -0.24% |
| Week 5 | $1.27 | $1.56 | $1.91 | -0.30% |
| Week 6 | $1.24 | $1.55 | $1.95 | -0.36% |
| Week 7 | $1.22 | $1.55 | $1.98 | -0.42% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention and treatment.
The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. 60 Degrees Pharmaceuticals, Inc.
was founded in 2010 and is headquartered in Washington, District Of Columbia.
SXTP is the asset name for 60 Degrees Pharmaceuticals, Inc. It is currently priced at $1.62 per share and has a market capitalization of $4.31M. It is ranked 5367 by market capitalization.
A major floor 26.5% below — a decisive break under it would weaken the trend.
The nearest floor, 12.8% below — buyers have tended to step in here.
The nearest ceiling, 14.1% above — a clean break opens room to run.
A major ceiling 106.4% above — clearing it would confirm fresh momentum.
Key SXTP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SXTP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.59 | Sell | $1.59 | Sell |
| MA 10 | $1.66 | Sell | $1.62 | Sell |
| MA 20 | $1.61 | Sell | $1.61 | Sell |
| MA 50 | $1.54 | Buy | $1.65 | Sell |
| MA 100 | $1.85 | Sell | $2.05 | Sell |
| MA 200 | $3.07 | Sell | $4.66 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.56 | Neutral |
| Stoch RSI (14) | 4.34 | Buy |
| CCI (20) | -37.24 | Neutral |
| Williams %R (14) | -95.65 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -7.14 | Sell |
| Bollinger %B (20,2) | 0.39 | Neutral |
| Stochastic %K (14) | 4.35 | Buy |
| TRIX (15) | 0.37 | Buy |
| Awesome (5,34) | 0.05 | Buy |
| Ultimate (7,14,28) | 22.39 | Buy |
| Momentum (10) | -0.08 | Sell |
| Aroon Osc (25) | 40.00 | Buy |
| Hull MA (9) | 1.52 | Buy |
| ADX (14) | 14.75 | Neutral |
| ATR (14) | 0.04 | Info |
The 30-day technical picture shows a bullish stance with RSI(14) at 50 and moving averages at SMA50 of $1.54 and SMA200 of $3.14. Immediate support is listed at $1.36 and resistance at $1.78. The stock has traded within a 30-day range of $1.27 to $2.07, reflecting a narrow near-term fluctuation window.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.36 | $1.56 | $1.98 | 0% | Neutral | |
| $1.19 | $1.53 | $2.11 | -2% | Neutral | |
| $1.11 | $1.48 | $2.14 | -5% | Neutral | |
| $0.9792 | $1.35 | $2.01 | -13% | Neutral | |
| $0.9857 | $1.40 | $2.15 | -10% | Neutral | |
| $1.10 | $1.60 | $2.52 | +2% | Neutral | |
| $1.27 | $1.89 | $3.05 | +21% | Bullish | |
| $1.28 | $1.95 | $3.20 | +25% | Bullish | |
| $1.15 | $1.79 | $3.00 | +15% | Neutral | |
| $1.21 | $1.91 | $3.26 | +23% | Bullish | |
| $1.48 | $2.57 | $4.72 | +65% | Bullish | |
| $1.74 | $3.59 | $7.31 | +130% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.36 | $1.56 | $1.85 | +0.00% |
| August 2026 | $1.32 | $1.57 | $1.92 | +0.33% |
| September 2026 | $1.29 | $1.55 | $1.93 | -1.11% |
| October 2026 | $1.22 | $1.47 | $1.85 | -4.81% |
| November 2026 | $1.22 | $1.48 | $1.88 | +0.48% |
| December 2026 | $1.26 | $1.55 | $1.98 | +4.45% |
Click any year to see its month-by-month SXTP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The SXTP price prediction for 2026 points to an average of $1.56 (low $1.36, high $1.98) — a potential gain of 0% on today's $1.56. Price action looks broadly range-bound.
In 2027, SXTP is projected to trade between $1.19 and $2.11, averaging $1.53 — a potential decline of -2% from today's $1.56. That is -2% versus the projected 2026 average. A consolidation phase looks the most probable path here.
60 Degrees Pharmaceuticals, Inc.'s 2028 outlook centres on $1.48, within a $1.11 to $2.14 range. That is -3% versus the projected 2027 average. That marks a -5% change versus current levels. Price action looks broadly range-bound.
By 2029, SXTP could reach as high as $2.01, with a base case around $1.35 and support toward $0.9792 — roughly -13% from $1.56. A consolidation phase looks the most probable path here.
Expect SXTP to range from $0.9857 to $2.15 through 2030. The $1.40 average target implies a -10% move from current prices. That is up +3% on the projected 2029 average. Price action looks broadly range-bound.
The SXTP price prediction for 2031 points to an average of $1.60 (low $1.10, high $2.52) — a potential gain of +2% on today's $1.56. A consolidation phase looks the most probable path here.
In 2032, SXTP is projected to trade between $1.27 and $3.05, averaging $1.89 — a potential gain of +21% from today's $1.56. That is up +18% on the projected 2031 average. Momentum favours further upside here.
60 Degrees Pharmaceuticals, Inc.'s 2033 outlook centres on $1.95, within a $1.28 to $3.20 range. That is up +3% on the projected 2032 average. That marks a +25% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, SXTP could reach as high as $3.00, with a base case around $1.79 and support toward $1.15 — roughly +15% from $1.56. Price action looks broadly range-bound.
Expect SXTP to range from $1.21 to $3.26 through 2035. The $1.91 average target implies a +23% move from current prices. That is up +7% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The SXTP price prediction for 2040 points to an average of $2.57 (low $1.48, high $4.72) — a potential gain of +65% on today's $1.56. Momentum favours further upside here.
In 2050, SXTP is projected to trade between $1.74 and $7.31, averaging $3.59 — a potential gain of +130% from today's $1.56. That is up +39% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in SXTP today (≈ 641.025641 SXTP) could be worth
$2,299.2
+$1,299.2 (+130%) by 2050 · US Dollar
Based on the average projected SXTP price of $3.59 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SXTPwould be worth at today's price.
$1,000 invested in SXTP on Jul 10, 2025 (≈ 95.785444 SXTP) would be worth
$149.43
-$850.57 (-85.1%) today · 0.15× · US Dollar
Based on a SXTP entry price of $10.44 vs. today's $1.56.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.71 | $912.28 | -8.8% |
| 1 month ago | $1.38 | $1,130.43 | +13.0% |
| 3 months ago | $1.76 | $886.36 | -11.4% |
| 6 months ago | $2.28 | $683.01 | -31.7% |
| 1 year ago | $10.44 | $149.43 | -85.1% |
| All time (3.0y) ago | $1,123.2 | $1.39 | -99.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SXTP forecast.
Our base-case forecast reaches $3.10 around 2050.
Implied market cap at $3.10: $8.24M
The multi-year forecast shows a shift from a neutral near term to bullish longer term. In 2026 the average price is $1.62 with a range of $1.36 to $2.08 and a neutral sentiment. Beginning in 2032 the forecast turns bullish, with 2032’s average $1.96 (max $3.23) and ROI 21.2%, and 2033’s average $2.01 (max $3.38) with ROI 24.1%.
The outlook remains bullish for 2035 (avg $1.97, max $3.45; ROI 21.8%), 2040 (avg $2.67, max $5.03; ROI 64.8%), and 2050 (avg $3.67, max $7.71; ROI 126.5%). These are estimates and not guarantees, but the trajectory points to meaningful upside potential over the longer horizon while acknowledging inherent uncertainty and risk.
Tap a question to reveal the answer.
2030 forecast shows min $0.9868, avg $1.42, max $2.22 with ROI -12.2% and sentiment NEUTRAL.
Near term shows NEUTRAL sentiment, with a path to bullish conditions beginning in 2032. The 2032–2050 outlook includes higher averages and ROI reaching 21.2% (2032) to 126.5% (2050), but these are forecasts and not guarantees.
Yes. The 2033 forecast has an average of $2.01 and a max of $3.38, with a positive longer-term trajectory including a 2032 max of $3.23. Earlier years also show a path above $2, such as 2030 max $2.22.
2040 forecast: min $1.48, avg $2.67, max $5.03; ROI 64.8%; sentiment BULLISH.
2050 forecast: min $1.68, avg $3.67, max $7.71; ROI 126.5%; sentiment BULLISH.
60 Degrees Pharmaceuticals, Inc. Community Discussion
0Share your 60 Degrees Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.